This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:pathogenesis:microbiota:interaction [05.19.2020] – [Coronavirus] sallieq | home:pathogenesis:microbiota:interaction [05.23.2020] – [Coronavirus] sallieq | ||
---|---|---|---|
Line 2: | Line 2: | ||
====== Effects of bacteria and viruses on their human host ====== | ====== Effects of bacteria and viruses on their human host ====== | ||
- | < | + | < |
Line 52: | Line 52: | ||
chloroquine (({{pubmed> | chloroquine (({{pubmed> | ||
- | neuroinvasive potential(({{pubmed> | + | neuroinvasive potential(({{pubmed> |
Unique epidemiological and clinical features(({{pubmed> | Unique epidemiological and clinical features(({{pubmed> | ||
Line 70: | Line 70: | ||
February 2020 The multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine. (({{pubmed> | February 2020 The multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine. (({{pubmed> | ||
- | Drug used for Ebola is being tested on 600 participants in a study started March 15, 2020 and expected to complete in May 2020 [[https:// | + | **May 2020** Results of extensive study of [[https:// |
+ | |||
+ | 96 032 patients (mean age 53·8 years, 46·3% women) with COVID-19 were hospitalised during the study period and met the inclusion criteria. | ||
+ | |||
+ | Data from 671 hospitals in six continents | ||
+ | |||
+ | Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide), and patients who received none of these treatments formed the control group. Patients for whom one of the treatments of interest was initiated more than 48 h after diagnosis or while they were on mechanical ventilation, | ||
+ | |||
+ | After controlling for multiple confounding factors (age, sex, race or ethnicity, body-mass index, underlying cardiovascular disease and its risk factors, diabetes, underlying lung disease, smoking, immunosuppressed condition, and baseline disease severity), | ||
+ | |||
+ | The main outcomes of interest were in-hospital mortality and the occurrence of de-novo ventricular arrhythmias (non-sustained or sustained ventricular tachycardia or ventricular fibrillation). | ||
+ | |||
+ | Compared with the control group (0·3%), hydroxychloroquine (6·1%; 2·369, 1·935–2·900), | ||
+ | |||
+ | |||
+ | When compared with mortality in the control group (9·3%), hydroxychloroquine (18·0%; hazard ratio 1·335, 95% CI 1·223–1·457), | ||
[[https:// | [[https:// | ||
[[https:// | [[https:// | ||
+ | |||
+ | Drug used for Ebola is being tested on 600 participants in a study started March 15, 2020 and expected to complete in May 2020 [[https:// | ||
+ | |||
+ | [[https:// | ||
+ | |Laboratory experiment shows Ivermectin can kill the virus within 48 hours in cell culture]] | ||
+ | |||
[[https:// | [[https:// | ||